2025-06-04-Bernstein-欧洲生物制药_全球疫苗入门_预防永远是最好的药物_112页_21mb

Summary of the European Biopharma Report: Vaccines and Key Players

Key Recommendations:

• Sanofi (O): Outperform rating with €124 price target. Strong EPS growth, improving pipeline visibility, and effective life cycle management.
• GSK (LN): Outperform rating with £3,290 price target. Undervalued market cap, potential catalysts for multiple expansion, despite pipeline challenges.
• Pfizer (M): Market-Perform rating at $30. Low guidance due to LOE exposure; recent setbacks in key pipeline drugs.
• Merck & Co. (M): Market-Perform rating at $95. Keytruda's LOE challenges margin more than consensus estimates.
• Moderna (M): Market-Perform rating at $28. Near-term revenue headwinds but potential upside from CMV vaccine.

Key Insights:

1. Vaccines are High-Barrier, High-Value Segment:

   • Entry Barriers: Regulated, expensive manufacturing, and strong IP protection create a challenging landscape.
   • Value Proposition: Vaccines are cost-effective due to prevention-focused healthcare savings (e.g., Gardasil saves ~$100k per woman vs. treatment costs).

2. Sanofi and GSK as Best Market Exposure:

   • Sanofi: Strong growth in vaccines (Shingrix, RSV) and diversified portfolio (Dupixent offsets vaccine risks).
   • GSK: Undervalued with high-growth vaccines (Shingrix, Arexvy); HIV pipeline and pharma exposure add complexity.

3. Declining Coverage and Market Dynamics:

   • US Vaccination Rates: Flu and RSV coverage dropped 5-8 percentage points in 2023-24 due to pandemic fatigue.
   • Geographic Hubs: Europe and US lead sales, while Emerging Markets offer untapped growth (e.g., pneumococcal, RSV).

4. Innovations and Future Trends:

   • mRNA Technologies: Faster production and adaptable to RSV, flu, and cancer vaccines.
   • Universal Vaccines: Long-term goal (2030s) for RSV and flu; current focus on broadening protection (e.g., Shingrix's 10-year efficacy).

Investment Implications:

• Outlook: Vaccines industry maintains ~4% CAGR (2024-2034) driven by demographics, R&D advancements, and sustained demand.
• Risks: Regulatory hurdles, pipeline failures, competition from new technologies (Moderna, Pfizer), and pricing pressures.

Key Takeaways:

• Vaccines offer uniquely high entry barriers and value, making Sanofi and GSK preferred exposure.
• Emerging markets, mRNA vaccines, and next-gen serotypes (e.g., RSV, CMV) represent growth opportunities.
• Pricing and regulatory approval timelines remain critical factors, especially for innovative vaccines.